+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Lewy Body Dementia Treatment Market by Treatment Modality, Distribution Channel, End User, Route of Administration, Treatment Line - Global Forecast to 2030- Product Image
Lewy Body Dementia Treatment Market by Treatment Modality, Distribution Channel, End User, Route of Administration, Treatment Line - Global Forecast to 2030- Product Image
Sale

Lewy Body Dementia Treatment Market by Treatment Modality, Distribution Channel, End User, Route of Administration, Treatment Line - Global Forecast to 2030

  • PDF Icon

    Report

  • 196 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5674515
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Lewy Body Dementia Treatment Market grew from USD 6.60 billion in 2024 to USD 7.20 billion in 2025. It is expected to continue growing at a CAGR of 8.66%, reaching USD 10.88 billion by 2030.

Understanding the Evolving Landscape of Lewy Body Dementia Treatment

The burgeoning complexity of Lewy body dementia treatment demands a concise, authoritative overview that sets the tone for an in-depth exploration of market dynamics, forces, and opportunities. This executive summary distills critical insights into the factors shaping the therapeutic landscape, providing decision-makers with a clear understanding of technological advances, regulatory developments, and patient-centric drivers. By examining macroeconomic pressures, evolving patient needs, and scientific breakthroughs, this overview prepares stakeholders to navigate shifting paradigms and align strategic initiatives with emerging imperatives.

This introductory section outlines the scope of our analysis, which spans treatment modalities, distribution channels, end-user segments, and regional landscapes. It underscores the importance of an integrated perspective that connects clinical innovation with market viability and end-user adoption. In doing so, it establishes a roadmap for subsequent sections, guiding readers through transformative shifts, policy impacts, segmentation nuances, and competitive strategies. Ultimately, this introduction underscores the imperative for agile, data-driven decision-making in addressing the unmet needs of patients living with Lewy body dementia.

Transformative Shifts Reshaping the Treatment Paradigm

Over recent years, the field of Lewy body dementia treatment has experienced several transformative shifts that are redefining patient care and therapeutic development. Advances in non-invasive diagnostic tools and digital biomarkers have enhanced early detection rates, enabling clinicians to tailor interventions more precisely and improve long-term outcomes. Concurrently, the integration of cognitive and occupational therapies with pharmacological regimens underscores a holistic approach, recognizing that multimodal treatment pathways yield synergistic benefits for cognitive and motor symptoms alike.

At the same time, the emergence of novel pharmacotherapies targeting alpha-synuclein aggregation and neuroinflammation signals a paradigm shift from symptom management toward disease-modifying strategies. Regulatory agencies have responded with accelerated approval pathways and adaptive licensing models, incentivizing innovation while balancing safety and efficacy criteria. This evolving framework encourages collaboration between pharmaceutical developers, academic institutions, and patient advocacy groups, fostering a more patient-centered research ecosystem. These combined forces are reshaping the trajectory of Lewy body dementia care, opening new avenues for personalized medicine and long-term patient support.

Assessing the Ripple Effects of United States Tariffs in 2025

The enactment of new United States tariffs in 2025 has introduced multifaceted repercussions across the Lewy body dementia treatment value chain. Import levies on active pharmaceutical ingredients and specialized medical devices have elevated production costs, compelling manufacturers to reassess pricing strategies and supply chain routes. Simultaneously, fluctuations in raw material availability have prompted companies to diversify sourcing frameworks, seeking partnerships with regional suppliers to mitigate exposure to tariff-induced volatility.

Beyond upstream effects, downstream distribution channels have adjusted to altered cost structures. Hospital and retail pharmacies face margin pressures that can translate into constrained patient access, while online pharmacies navigate complex cross‐border compliance challenges. At the same time, end-user institutions-ranging from home care services to specialty clinics-are recalibrating procurement budgets in response to these added expenses. In turn, this has spurred intensified negotiation between payers, providers, and manufacturers to preserve treatment affordability.

Overall, the cumulative impact of the 2025 tariff changes has underscored the necessity for resilient operational models and dynamic pricing frameworks, compelling industry stakeholders to embrace agility and strategic foresight in a newly tariff-conscious environment.

Unveiling Key Insights Across Diverse Market Segments

The market for Lewy body dementia treatment unfolds across multiple dimensions, each offering distinct insights into patient needs and commercial potential. Treatment modality encompasses an interplay between non-pharmacological approaches-such as cognitive therapy, occupational therapy, physical therapy, and speech therapy-and pharmacological options, including cholinesterase inhibitors, dopaminergic agents, and NMDA receptor antagonists. Within the cholinesterase inhibitor category, compounds like donepezil, galantamine, and rivastigmine demonstrate varied efficacy profiles, influencing prescribing patterns and patient adherence.

Distribution channels further delineate market access, with hospital pharmacies, online pharmacies, and retail pharmacies each navigating unique regulatory, logistical, and consumer behavior considerations. End-user segmentation highlights the divergent needs of home care services, hospitals, and specialty clinics, reflecting differences in resource intensity, caregiver expertise, and patient acuity. Meanwhile, the route of administration-spanning intravenous, oral, and transdermal formulations-impacts dosing convenience and tolerability, driving patient preference and reimbursement debates. Finally, treatment line analysis, which differentiates first-line, second-line, and third-line interventions, informs competitive dynamics, pipeline prioritization, and market penetration strategies.

By synthesizing these segmentation insights, stakeholders can pinpoint high-value niches, optimize product portfolios, and align resource allocation with evolving clinical and commercial benchmarks.

Regional Nuances Driving Market Momentum Worldwide

Geographic variations play a pivotal role in shaping the trajectory of Lewy body dementia treatment, with each region presenting distinct regulatory frameworks, healthcare infrastructures, and patient demographics. In the Americas, substantial public and private investment in neurological research, combined with established reimbursement mechanisms, fuels rapid adoption of both established and emerging therapies. Meanwhile, payers and providers collaborate on risk-sharing agreements to address the high cost of innovative treatments, reinforcing market resilience.

Within Europe, the Middle East, and Africa, heterogeneous regulatory landscapes and variable healthcare spending influence market uptake. Western European nations often lead in reimbursement approvals, while emerging markets in Eastern Europe and the Gulf region display significant growth potential as healthcare modernization accelerates. In sub-Saharan Africa, challenges related to diagnostic infrastructure and specialist availability underscore the importance of targeted capacity-building initiatives.

Asia-Pacific markets exhibit dynamic growth trajectories driven by increasing prevalence, expanding middle-class demographics, and progressive reimbursement reforms. Countries such as Japan and South Korea benefit from advanced clinical trial networks and aging populations that prioritize neurological health. In contrast, Southeast Asian nations leverage public-private partnerships to enhance diagnostic capabilities and bolster treatment access. Collectively, these regional nuances guide global market strategies and investment priorities.

Competitive Landscape and Strategic Moves of Leading Companies

The competitive landscape in Lewy body dementia treatment is marked by a convergence of established pharmaceutical powerhouses and agile biotechs pursuing novel mechanisms of action. Leading companies leverage diversified pipelines encompassing small molecules, biologics, and digital therapeutics to address both cognitive decline and motor dysfunction. Strategic collaborations between large pharmaceutical firms and specialized biotech innovators have accelerated clinical development, granting access to complementary expertise in alpha-synuclein targeting, neuroinflammation modulation, and gene therapy approaches.

In parallel, companies with legacy cholinesterase inhibitor portfolios are fortifying their market positions through label expansions and combination therapy trials. Meanwhile, emerging players are forging alliances with academic centers to validate digital biomarkers and remote monitoring platforms, enhancing real-world evidence generation. Mergers and acquisitions continue to reshape the landscape, with established players acquiring biotech startups to secure late-stage assets and strengthen differentiated pipelines.

As competition intensifies, pricing strategies, payer engagements, and patient-centric support programs will increasingly influence market share. Companies that successfully integrate clinical innovation with robust commercialization frameworks stand to capture significant value in this evolving therapeutic arena.

Actionable Strategies for Industry Leaders to Navigate Change

Industry leaders must adopt proactive strategies to navigate the complexities of the Lewy body dementia market and capitalize on emerging opportunities. Firstly, integrating multidimensional patient data-encompassing clinical, genomic, and digital biomarkers-can inform precision medicine initiatives and differentiate product offerings. Secondly, optimizing supply chain resilience through dual‐sourcing agreements and regional manufacturing hubs will mitigate tariff exposures and ensure consistent product availability.

Furthermore, fostering collaborative partnerships with payers, providers, and patient advocacy organizations can accelerate reimbursement approvals and broaden access pathways. Leaders should also invest in real-world evidence programs to substantiate long-term value propositions and support premium pricing. In parallel, diversifying route-of-administration portfolios by developing transdermal or long-acting formulations can enhance patient adherence and reduce caregiver burden.

Finally, establishing agile commercial models that leverage digital engagement tools and telehealth platforms will align with shifting care paradigms and empower healthcare professionals to deliver personalized treatment regimens. By implementing these approaches, organizations can strengthen their competitive positioning and drive sustainable growth in the years ahead.

Robust Methodology Underpinning Research Insights

This analysis draws upon a rigorous methodology combining comprehensive secondary intelligence with targeted primary research. We systematically reviewed regulatory filings, clinical trial registries, and peer-reviewed literature to assemble a robust evidence base. Concurrently, the research team conducted in-depth interviews with key opinion leaders, neurologists, and care providers to validate findings and uncover nuanced market dynamics.

Quantitative data were triangulated across multiple proprietary and public databases to ensure accuracy and consistency. Market segmentation parameters were defined in collaboration with subject matter experts to reflect clinical relevance and commercial feasibility. Regional insights were refined through a combination of country-level policy reviews and proprietary market access assessments.

The result is an integrated framework that captures evolving treatment paradigms, competitive positioning, and regulatory trajectories. Quality control measures, including peer review and data verification protocols, reinforce the reliability of this report’s conclusions and strategic recommendations.

Concluding Perspectives and Future Outlook

In summary, the Lewy body dementia treatment landscape is undergoing a period of rapid transformation driven by scientific breakthroughs, shifting regulatory incentives, and evolving patient care models. The convergence of non-pharmacological and pharmacological innovations, coupled with dynamic tariff environments and regional market nuances, underscores the complexity and opportunity inherent in this space. Companies that align strategic investments with patient-centric imperatives and data-driven decision-making will be best positioned to deliver meaningful clinical outcomes and capture sustainable commercial value.

Moving forward, stakeholder collaboration across the healthcare ecosystem-from biotech innovators to payers and caregiver networks-will be essential to overcoming access barriers and accelerating the development of disease-modifying therapies. By leveraging the insights presented in this executive summary, leaders can chart a course that addresses unmet needs, fosters innovation, and ultimately enhances the quality of life for patients living with Lewy body dementia.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Treatment Modality
    • Non Pharmacological
      • Cognitive Therapy
      • Occupational Therapy
      • Physical Therapy
      • Speech Therapy
    • Pharmacological
      • Cholinesterase Inhibitors
        • Donepezil
        • Galantamine
        • Rivastigmine
      • Dopaminergic Agents
      • NMDA Receptor Antagonists
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • End User
    • Home Care Services
    • Hospitals
    • Specialty Clinics
  • Route Of Administration
    • Intravenous
    • Oral
    • Transdermal
  • Treatment Line
    • First Line
    • Second Line
    • Third Line
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Eisai Co., Ltd.
  • Biogen Inc.
  • Novartis AG
  • Eli Lilly and Company
  • Pfizer Inc.
  • Roche Holding AG
  • H. Lundbeck A/S
  • UCB Pharma S.A.
  • ACADIA Pharmaceuticals Inc.
  • Axovant Sciences Ltd.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Lewy Body Dementia Treatment Market, by Treatment Modality
8.1. Introduction
8.2. Non Pharmacological
8.2.1. Cognitive Therapy
8.2.2. Occupational Therapy
8.2.3. Physical Therapy
8.2.4. Speech Therapy
8.3. Pharmacological
8.3.1. Cholinesterase Inhibitors
8.3.1.1. Donepezil
8.3.1.2. Galantamine
8.3.1.3. Rivastigmine
8.3.2. Dopaminergic Agents
8.3.3. NMDA Receptor Antagonists
9. Lewy Body Dementia Treatment Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacies
9.3. Online Pharmacies
9.4. Retail Pharmacies
10. Lewy Body Dementia Treatment Market, by End User
10.1. Introduction
10.2. Home Care Services
10.3. Hospitals
10.4. Specialty Clinics
11. Lewy Body Dementia Treatment Market, by Route of Administration
11.1. Introduction
11.2. Intravenous
11.3. Oral
11.4. Transdermal
12. Lewy Body Dementia Treatment Market, by Treatment Line
12.1. Introduction
12.2. First Line
12.3. Second Line
12.4. Third Line
13. Americas Lewy Body Dementia Treatment Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Lewy Body Dementia Treatment Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Lewy Body Dementia Treatment Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Eisai Co., Ltd.
16.3.2. Biogen Inc.
16.3.3. Novartis AG
16.3.4. Eli Lilly and Company
16.3.5. Pfizer Inc.
16.3.6. Roche Holding AG
16.3.7. H. Lundbeck a/S
16.3.8. UCB Pharma S.A.
16.3.9. ACADIA Pharmaceuticals Inc.
16.3.10. Axovant Sciences Ltd.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. LEWY BODY DEMENTIA TREATMENT MARKET MULTI-CURRENCY
FIGURE 2. LEWY BODY DEMENTIA TREATMENT MARKET MULTI-LANGUAGE
FIGURE 3. LEWY BODY DEMENTIA TREATMENT MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2030 (%)
FIGURE 8. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. LEWY BODY DEMENTIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. LEWY BODY DEMENTIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. LEWY BODY DEMENTIA TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY COGNITIVE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY OCCUPATIONAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY SPEECH THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DONEPEZIL, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY GALANTAMINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY RIVASTIGMINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DOPAMINERGIC AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY HOME CARE SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 56. CANADA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 57. CANADA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 58. CANADA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 59. CANADA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 60. CANADA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 61. CANADA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 62. CANADA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 63. CANADA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 64. MEXICO LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 65. MEXICO LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 66. MEXICO LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 67. MEXICO LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 68. MEXICO LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 69. MEXICO LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 70. MEXICO LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 71. MEXICO LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 88. EUROPE, MIDDLE EAST & AFRICA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 94. EUROPE, MIDDLE EAST & AFRICA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 97. UNITED KINGDOM LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 98. UNITED KINGDOM LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 99. UNITED KINGDOM LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 100. UNITED KINGDOM LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 101. UNITED KINGDOM LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 102. UNITED KINGDOM LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 103. UNITED KINGDOM LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 104. UNITED KINGDOM LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 105. GERMANY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 106. GERMANY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 107. GERMANY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 108. GERMANY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 109. GERMANY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 110. GERMANY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 111. GERMANY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 112. GERMANY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 113. FRANCE LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 114. FRANCE LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 115. FRANCE LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 116. FRANCE LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 117. FRANCE LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 118. FRANCE LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 119. FRANCE LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 120. FRANCE LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 121. RUSSIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 122. RUSSIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 123. RUSSIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 124. RUSSIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 125. RUSSIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 126. RUSSIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 127. RUSSIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 128. RUSSIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 129. ITALY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 130. ITALY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 131. ITALY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 132. ITALY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 133. ITALY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 134. ITALY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 135. ITALY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 136. ITALY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 137. SPAIN LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 138. SPAIN LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 139. SPAIN LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 140. SPAIN LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 141. SPAIN LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 142. SPAIN LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 143. SPAIN LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 144. SPAIN LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 145. UNITED ARAB EMIRATES LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 146. UNITED ARAB EMIRATES LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 147. UNITED ARAB EMIRATES LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 148. UNITED ARAB EMIRATES LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 149. UNITED ARAB EMIRATES LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 150. UNITED ARAB EMIRATES LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 151. UNITED ARAB EMIRATES LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 152. UNITED ARAB EMIRATES LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 153. SAUDI ARABIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 154. SAUDI ARABIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 155. SAUDI ARABIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 156. SAUDI ARABIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 157. SAUDI ARABIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 158. SAUDI ARABIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 159. SAUDI ARABIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 160. SAUDI ARABIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 161. SOUTH AFRICA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 162. SOUTH AFRICA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 163. SOUTH AFRICA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 164. SOUTH AFRICA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 166. SOUTH AFRICA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 167. SOUTH AFRICA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 168. SOUTH AFRICA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 169. DENMARK LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 170. DENMARK LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 171. DENMARK LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 172. DENMARK LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 173. DENMARK LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 174. DENMARK LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 175. DENMARK LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 176. DENMARK LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 177. NETHERLANDS LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 178. NETHERLANDS LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 179. NETHERLANDS LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 180. NETHERLANDS LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 181. NETHERLANDS LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 182. NETHERLANDS LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 183. NETHERLANDS LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 184. NETHERLANDS LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 185. QATAR LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 186. QATAR LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 187. QATAR LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 188. QATAR LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 189. QATAR LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 190. QATAR LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 191. QATAR LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 192. QATAR LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 193. FINLAND LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 194. FINLAND LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 195. FINLAND LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 196. FINLAND LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 197. FINLAND LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 198. FINLAND LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 199. FINLAND LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 200. FINLAND LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 201. SWEDEN LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 202. SWEDEN LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 203. SWEDEN LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 204. SWEDEN LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 205. SWEDEN LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 206. SWEDEN LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 207. SWEDEN LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 208. SWEDEN LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 209. NIGERIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 210. NIGERIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 211. NIGERIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 212. NIGERIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 213. NIGERIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 214. NIGERIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 215. NIGERIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 216. NIGERIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 217. EGYPT LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 218. EGYPT LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 219. EGYPT LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 220. EGYPT LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 221. EGYPT LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 222. EGYPT LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 223. EGYPT LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 224. EGYPT LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 225. TURKEY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 226. TURKEY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 227. TURKEY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 228. TURKEY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 229. TURKEY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 230. TURKEY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 231. TURKEY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 232. TURKEY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 233. ISRAEL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 234. ISRAEL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 235. ISRAEL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 236. ISRAEL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 237. ISRAEL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 238. ISRAEL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 239. ISRAEL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 240. ISRAEL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 241. NORWAY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 242. NORWAY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 243. NORWAY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 244. NORWAY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 245. NORWAY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 246. NORWAY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 247. NORWAY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 248. NORWAY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 249. POLAND LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 250. POLAND LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 251. POLAND LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 252. POLAND LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 253. POLAND LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 254. POLAND LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 255. POLAND LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 256. POLAND LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 257. SWITZERLAND LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 258. SWITZERLAND LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 259. SWITZERLAND LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 260. SWITZERLAND LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 261. SWITZERLAND LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 262. SWITZERLAND LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 263. SWITZERLAND LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 264. SWITZERLAND LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 265. ASIA-PACIFIC LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 266. ASIA-PACIFIC LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 267. ASIA-PACIFIC LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 268. ASIA-PACIFIC LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 269. ASIA-PACIFIC LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 270. ASIA-PACIFIC LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 271. ASIA-PACIFIC LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 272. ASIA-PACIFIC LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 273. ASIA-PACIFIC LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 274. CHINA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 275. CHINA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 276. CHINA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 277. CHINA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 278. CHINA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 279. CHINA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 280. CHINA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 281. CHINA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 282. INDIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 283. INDIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 284. INDIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 285. INDIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 286. INDIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 287. INDIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 288. INDIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 289. INDIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 290. JAPAN LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 291. JAPAN LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 292. JAPAN LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 293. JAPAN LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 294. JAPAN LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 295. JAPAN LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 296. JAPAN LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 297. JAPAN LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 298. AUSTRALIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 299. AUSTRALIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 300. AUSTRALIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 301. AUSTRALIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 302. AUSTRALIA

Companies Mentioned

The companies profiled in this Lewy Body Dementia Treatment market report include:
  • Eisai Co., Ltd.
  • Biogen Inc.
  • Novartis AG
  • Eli Lilly and Company
  • Pfizer Inc.
  • Roche Holding AG
  • H. Lundbeck A/S
  • UCB Pharma S.A.
  • ACADIA Pharmaceuticals Inc.
  • Axovant Sciences Ltd.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages196
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 7.2 Billion
Forecasted Market Value ( USD ) by 2030 $ 10.88 Billion
Compound Annual Growth Rate8.6%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Lewy Body Dementia Treatment Market Report 2025 - Product Image

Lewy Body Dementia Treatment Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Lewy Boy Dementia Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

Lewy Boy Dementia Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 180 Pages
  • Global
From
Dementia Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Dementia Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 186 Pages
  • Global
From
Lewy Body Dementia (LBD) - Pipeline Insight, 2025 - Product Image

Lewy Body Dementia (LBD) - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
Lewy Body Dementia Treatment Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Lewy Body Dementia Treatment Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 83 Pages
  • Global
From

About the Dementia Drug Market

The Dementia Drug market is a subset of the Central Nervous System Drugs market, which includes drugs used to treat neurological disorders. Dementia drugs are used to treat the cognitive decline associated with Alzheimer's disease, vascular dementia, and other forms of dementia. These drugs are typically prescribed to improve memory, thinking, and behavior, as well as to slow the progression of the disease. Common dementia drugs include cholinesterase inhibitors, memantine, and glutamate modulators. Some companies in the Dementia Drug market include Pfizer, Novartis, Merck, and Eli Lilly. Other companies include Biogen, AstraZeneca, and Johnson & Johnson. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.